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Abstract 
Background : Fragile X syndrome (FXS), the most common monogenetic cause of 
intellectual disability and autism spectrum disorders, is characterized by behavioral 
and physical problems. There is currently no adequate treatment available. While 
animal model studies seemed extremely promising, no success has been achieved in 
the larger clinical trials with human FXS patients. This short review describes the 
steps that have been taken in the development of a targeted treatment for FXS. 
Possible reasons for the lack of translation between animal models and human FXS 
patients are being explored and solutions are being proposed. The FXS story 
illustrates pitfalls and possibilities in translational research, that might especially be 
applicable for other neurodevelopmental disorders as well 
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INTRODUCTION 
 Fragile X syndrome (FXS) is the most common 
monogenetic cause of intellectual disability and autism 
spectrum disorders, affecting about 1:7000 males 1,2. The 
disorder is caused by a CGG repeat expansion in the 5’ 
UTR of the FMR1 gene. This repeat expansion leads to 
silencing of the FMR1 gene and lack of its protein 
product, FMRP. Since FMRP plays an important role in 
regulation of synaptic plasticity in the brain, its lack 
leads to several neurocognitive and behavioral problems. 
Hence, FXS is accompanied by intellectual disability, 
autism spectrum disorders, executive function deficits, 
attention and hyperactivity disorder, aggression and 
anxiety, amongst others. Also medical problems are 
frequent, including epilepsy and frequent otitis media in 
children 3,4. Patients are usually attending special 
education or end up in institutions. Emotional and 
behavioral problems are most disabling and are often 
treated with non-specific symptomatic pharmacological 
and supportive treatments. However, these interventions 
are mostly insufficient and there is no disease-modifying 
effective therapy, targeting the cognitive, behavioral, 
emotional or medical problems.  
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This lack of effective therapy leaves parents, care-givers 
and medical professionals with little options to alleviate 
the burden of taking care of a patient with FXS. 
Moreover, its relatively high frequency together with the 
life-long intellectual, and sometimes extreme behavioral 
and physical disabilities and the hereditary character of 
the disease, make FXS very costly for society. Hence, an 
effective targeted disease modifying therapy, especially 
affecting the behavioral, emotional and intellectual 
problems, is important for patients, caregivers, 
physicians and society. 
 
THE SEARCH FOR A TARGETED TREATMENT 
  Identification of the FMR1 gene as the causative  
gene 5, opened possibilities to study the disease in animal 
models. In the past decades, much research has been 
performed on FXS animal models, for example the Fmr1 
knock-out (KO) mouse, the fruit fly and the zebrafish. 
This research identified the function of the FMR1 protein 
product, FMRP, as a key regulator of the neuronal 
synaptic plasticity, by binding and regulating the local 
translation of target mRNAs. Many synaptic pathways 
have been shown to be disturbed in FXS 6. A few of these 
include the metabotropic glutamate type 5 receptor 
(mGluR5) pathway, the gamma-Aminobutyric acid 
(GABA)ergic pathway, the endocannabinoid pathway, 
the matrix metalloproteinase 9 (MMP9) pathway and 
intracellular signaling pathways (e.g. extracellular signal 
related kinase (ERK), mammalian target of rapamycin 
13 
 
 
Journal of Biomedicine and Translational Research, 5 (1) 2019, 12-14 
(mTOR) and glycogen synthase kinase-3 (GSK3)). Also 
intracellular downstream mRNA and protein targets of 
FMRP have been shown to be involved 6,7. All these 
pathways are part of the immensely complex network, 
balancing the neurons’ excitatory and inhibitory 
function and thus regulating synaptic plasticity.  
 Since the identification of the pathways involved in 
FXS, many studies have focused on preclinical research 
targeting the aberrant pathways in FXS animal models, 
leading to promising therapeutic results 6,8. While FXS 
initially seemed to be a complex and untreatable disease, 
it unexpectedly held promise of a therapy. 
Enthusiastically, clinical studies with FXS patients 
followed, targeting several pathways, including the 
mGluR5 pathway, GABAergic pathway, MMP9 and 
GSK3 6,7. Although some of the smaller, controlled and 
non-controlled trials seemed to yield some improvement 
in behavior, none of the larger, placebo-controlled trials 
have met their endpoints and proved efficacious in FXS 
patients 9. What is the reason that the promising animal 
studies could not be translated into a functional therapy 
for humans? What went wrong?  
 
POSSIBLE REASONS AND SOLUTIONS FOR 
THE LACK OF TRANSLATION 
 Clearly some issues need to be addressed, before the 
FXS research field can continue its search for a therapy. 
One of the major question is: are animal models suitable 
in modeling the human disease in the search of a 
therapy? Although animal models are indispensable in 
studying human diseases and in preclinical assessment 
of treatment, there are of course important differences 
between animals and humans. The Fmr1 KO mouse 
shows many similarities to the human disease, including 
macro-orchidism, behavioral and cognitive features 10. 
However, many of the phenotypes are subtle in the 
mouse model. Moreover, publications have shown great 
differences in their results, which is possibly accountable 
for by different genetic backgrounds and the setup of 
extreme controlled laboratory experimental protocols 
10,11. Results from studies in only one animal model 
cannot be generalized to humans 12. Possibly, 
reproducing successful results in several genetic 
backgrounds of several different animal species, could 
more precisely predict a chance for successful 
translation.  
 Another important limitation of the FXS studies are 
the used outcome measures, in mice as well as in humans 
6,13. To determine an effect of treatment, changes of 
relevant and important phenotypes should be used as 
outcome measures. However, many of the outcome 
measures used in animal models are probably not, or 
poorly, translatable to human functioning. In addition, 
biochemical measures, electrophysiological and 
microscopic morphological measures are often difficult 
to translate into relevant clinically functional 
improvement. In the clinical trial setting, most used 
outcome measures were care-giver rated questionnaires. 
Those are very prone to large placebo effects and are not 
objective. Currently, efforts are ongoing in the 
development of relevant and more objective outcome 
measures, that preferably should be usable in humans as 
well as in animal models. When using questionnaires, 
those should be validated for disease modifying therapy 
and more extensive training of the caregiver is needed to 
secure reliable results. Also, more objective, relevant and 
accessible outcome measures should be explored in their 
suitability for clinical trials, including endophenotypes 
like the eye-blink test, biomarkers, functional MRI 
(fMRI), functional near-infrared spectroscopy (fNIRS), 
Transcranial Magnetic Stimulation (TMS) and electro-
encephalogram (EEG).  
 The trial design could pose another important 
limitation in FXS studies. In fact, current trial design is 
probably not suitable to investigate disease modifying 
treatments for rare diseases, especially in the case of 
neurodevelopmental disorders. Typically, for safety and 
ethical reasons studies are not performed in very young 
children and are often carried out for a short period of 
time. However, in neurodevelopmental disorders 
treatment from a very young age should probably be 
aspired, as well as a longer duration of treatment. 
Recently, a trial has been initiated treating young children 
with the mGluR5-antagonist mavoglurant 
(NCT02920892). Additionally, drug treatment should be 
combined with environmental enrichment, to secure 
controlled stimulation of synaptic plasticity 14.  
 Finally, the least addressed but probably most 
important issue, concerns the need to target more than 
one pathway simultaneously. Considering the large 
number of pathways and downstream mRNA’s and 
proteins involved, it is highly unlikely that targeting only 
one of these would be enough to ameliorate the disorder 
11. Only a few studies have focused on combination 
therapy, targeting more than one pathway, including 
studies targeting the mGluR5 and GABAergic pathway 
simultaneously 15,16 and the serotonin and dopamine 
pathways simultaneously 17. These studies do support the 
theory that those different pathways are interconnected in 
a delicate balance. However, a tremendous fine-tuning 
will presumably be needed to restore the synaptic 
plasticity at the individual level. Theoretically, the most 
effective treatment would be to reactivate endogenous 
transcription of the FMR1 gene, preferably at a young 
age. Recently, efforts to reactivate transcription have 
been made successfully in cell models, using 
CRISPR/Cas9 and small molecules 18,19. However, these 
interventions are currently far from applicable in the 
clinical setting. 
 
CONCLUSION 
 While the quest for a targeted treatment for FXS is still 
ongoing, lessons that have been learned so far are being 
addressed in new approaches. These lessons are not only 
relevant for FXS, but could be generalized for all 
neurodevelopmental disorders for which a disease 
modifying therapy is being developed, or even 
translational medicine in general. Studies are performed 
exploring possibilities in the use of other disease models 
(e.g. other animal models, organoids and organ on a chip), 
outcome measures and alternative trial design. Tackling 
the complex issue of combination therapy is probably 
even more challenging, and should be considered in future 
studies. Perhaps, in the near future, successful and safe 
reactivation of transcription of the FMR1 gene will be 
feasible, opening new possibilities. 
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